Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study proposed the optimal definition of biochemical recurrence (BCR) after salvage radiotherapy (SRT) following radical prostatectomy for prostate cancer. Materials and methods: Among 1,117 patients who had received SRT, data from 205 hormone-naïve patients who experienced post-SRT prostate-specific antigen (PSA) elevation were included in a multi-institutional database. The primary endpoint was to determine the PSA parameters predictive of distant metastasis (DM). Absolute serum PSA levels and the prostate-specific antigen doubling time (PSA-DT) were adopted as PSA parameters. Results: When BCR was defined based on serum PSA levels ranging from 0.4 ng/mL to nadir+2.0 ng/mL, the 5-year probability of DM was 27.6%-33.7%. The difference in the 5-year probability of DM became significant when BCR was defined as a serum PSA level of 0.8 ng/ml or higher (1.0-2.0 ng/mL). Application of a serum PSA level of ≥ 0.8 ng/mL yielded a c-index value of 0.589. When BCR was defined based on the PSA-DT, the 5-year probability was 22.7%-39.4%. The difference was significant when BCR was defined as a PSA-DT ≤ 3 months and ≤ 6 months. Application of a PSA-DT ≤ 6 months yielded the highest c-index (0.660). These two parameters complemented each other; for patients meeting both PSA parameters, the probability of DM was 39.5%-44.5%; for those not meeting either parameter, the probability was 0.0%-3.1%. Conclusion: A serum PSA level > 0.8 ng/mL was a reasonable threshold for the definition of BCR after SRT. In addition, a PSA-DT ≤ 6 months was significantly predictive of subsequent DM, and combined application of both parameters enhanced predictability.
Abstract
Purpose: This study proposed the optimal definition of biochemical recurrence (BCR) after salvage radiotherapy (SRT) following radical prostatectomy for prostate cancer. Materials and methods: Among 1,117 patients who had received SRT, data from 205 hormone-naïve patients who experienced post-SRT prostate-specific antigen (PSA) elevation were included in a multi-institutional database. The primary endpoint was to determine the PSA parameters predictive of distant metastasis (DM). Absolute serum PSA levels and the prostate-specific antigen doubling time (PSA-DT) were adopted as PSA parameters. Results: When BCR was defined based on serum PSA levels ranging from 0.4 ng/mL to nadir+2.0 ng/mL, the 5-year probability of DM was 27.6%-33.7%. The difference in the 5-year probability of DM became significant when BCR was defined as a serum PSA level of 0.8 ng/ml or higher (1.0-2.0 ng/mL). Application of a serum PSA level of ≥ 0.8 ng/mL yielded a c-index value of 0.589. When BCR was defined based on the PSA-DT, the 5-year probability was 22.7%-39.4%. The difference was significant when BCR was defined as a PSA-DT ≤ 3 months and ≤ 6 months. Application of a PSA-DT ≤ 6 months yielded the highest c-index (0.660). These two parameters complemented each other; for patients meeting both PSA parameters, the probability of DM was 39.5%-44.5%; for those not meeting either parameter, the probability was 0.0%-3.1%. Conclusion: A serum PSA level > 0.8 ng/mL was a reasonable threshold for the definition of BCR after SRT. In addition, a PSA-DT ≤ 6 months was significantly predictive of subsequent DM, and combined application of both parameters enhanced predictability.
참고문헌 (15)
- Pound CR, "Natural history of progression after PSA elevation following radical prostatectomy", JAMA, 281, pp.1591~1597 (1999)
- Roehl KA, "Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3, 478 consecutive patients : long-term results", J Urol, 172, pp.910~914 (2004)
- Neuhof D, "Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy", Int J Radiat Oncol Biol Phys, 67, pp.1411~1417 (2007)
- Forman JD, "Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level", J Urol, 158, pp.1436~1439 (1997)
- 이성욱, "Clinical Outcomes of Postoperative Radiotherapy Following Radical Prostatectomy in Patients with Localized Prostate Cancer: A Multicenter Retrospective Study (KROG 18-01) of a Korean Population", Cancer Research and Treatment, 52(1), pp.167~180 (2020), 대한암학회
- D’Amico AV, "Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer", Cancer, 72, pp.2638~2643 (1993)
- Stish BJ, "Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer", J Clin Oncol, 34, pp.3864~3871 (2016)
- Bernard JR Jr, "Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer : dose-response analysis", Int J Radiat Oncol Biol Phys, 76, pp.735~740 (2010)
- Shipley WU, "Radiation with or without antiandrogen therapy in recurrent prostate cancer", N Engl J Med, 376, pp.417~428 (2017)
- Xie W, "Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer", J Clin Oncol, 35, pp.3097~3104 (2017)
- Gharzai LA, "Intermediate clinical endpoints for surrogacy in localised prostate cancer : an aggregate meta-analysis", Lancet Oncol, 22, pp.402~410 (2021)
- Stephenson AJ, "Defining biochemical recurrence of prostate cancer after radical prostatectomy : a proposal for a standardized definition", J Clin Oncol, 24, pp.3973~3978 (2006)
- Patel A, "Recurrence patterns after radical retropubic prostatectomy : clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen", J Urol, 158, pp.1441~1445 (1997)
- Hanks GE, "Prostatic-specific antigen doubling times in patients with prostate cancer : a potentially useful reflection of tumor doubling time", Int J Radiat Oncol Biol Phys, 27, pp.125~127 (1993)
- Jackson WC, "A prostate-specific antigen doubling time of < 6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy", Radiat Oncol, 8, pp.170~ (2013)